阿卡替尼Acalabrutinib 100mg

For adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. For adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have received at least one prior therapy.

The recommended dose is 100 mg per administration, orally approximately every 12 hours. Swallow the capsules whole with water, with or without food. Patients are advised not to open, break, or chew the capsules. Avoid use of this product in patients with severe hepatic impairment.

Severe and Opportunistic Infections: Monitor for signs and symptoms of infection and treat promptly. Hemorrhage: Monitor for bleeding and manage appropriately. Cytopenias: Monitor complete blood counts regularly. Second Primary Malignancies: Other malignancies have occurred, including skin cancer and other solid tumors. Advise patients to use sun protection measures. Arrhythmias: Monitor for symptoms of arrhythmias and manage accordingly. Hepatic Toxicity, Including Drug-induced Liver Injury: Monitor liver function throughout the course of treatment. Pregnancy: May cause fetal harm and difficult labor. Lactation: Breastfeeding is not recommended.

The most common adverse reactions (incidence ≥ 30%) are: anemia, neutropenia, upper respiratory tract infection, thrombocytopenia, headache, diarrhea, and musculoskeletal pain.

60 capsules per bottle.

Store at room temperature, below 30℃. Keep out of the reach of children.